TuHURA Biosciences (NASDAQ:HURA) Price Target Cut to $8.00 by Analysts at Maxim Group

TuHURA Biosciences (NASDAQ:HURA) had its price target decreased by Maxim Group from $15.00 to $8.00 in a research report sent to investors on Friday,Benzinga reports. Maxim Group currently has a buy rating on the stock.

HURA has been the subject of several other reports. Wall Street Zen raised TuHURA Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, September 20th. Weiss Ratings reiterated a “sell (e+)” rating on shares of TuHURA Biosciences in a research report on Wednesday, October 8th. Two analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, TuHURA Biosciences currently has an average rating of “Buy” and an average target price of $10.33.

TuHURA Biosciences Stock Up 0.5%

HURA stock traded up $0.01 during midday trading on Friday, hitting $2.05. The company’s stock had a trading volume of 162,567 shares, compared to its average volume of 279,969. TuHURA Biosciences has a 52-week low of $1.80 and a 52-week high of $7.20. The firm has a market capitalization of $105.08 million and a P/E ratio of -1.18. The firm has a 50-day simple moving average of $2.45 and a 200-day simple moving average of $2.74.

TuHURA Biosciences (NASDAQ:HURA) last announced its quarterly earnings data on Friday, November 14th. The company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.01.

Hedge Funds Weigh In On TuHURA Biosciences

Several hedge funds have recently bought and sold shares of HURA. Virtu Financial LLC acquired a new position in TuHURA Biosciences in the 3rd quarter valued at about $26,000. JPMorgan Chase & Co. purchased a new stake in TuHURA Biosciences during the second quarter valued at about $27,000. Intech Investment Management LLC purchased a new stake in shares of TuHURA Biosciences during the 2nd quarter worth about $29,000. Invesco Ltd. acquired a new stake in shares of TuHURA Biosciences in the second quarter worth $30,000. Finally, Merck & Co. Inc. acquired a new stake in TuHURA Biosciences in the 2nd quarter valued at $31,000. Hedge funds and other institutional investors own 0.62% of the company’s stock.

About TuHURA Biosciences

TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.